Pharmaceutical

Community health workers, experts in the in-between, fi...

"Having that kind of expertise on what it really means to walk in that person's ...

Kidney doctors push to protect patients by including di...

“We need to have some kind of reserve of machines that can be quickly accessed a...

Opinion: I saw firsthand in Nigeria that drugs alone ca...

“People infected with [tuberculosis] … need good living conditions, nutrition, a...

STAT+: ‘Shocking’ heat waves persist through August as ...

An already record-setting summer heat wave will continue through August and will...

STAT+: FDA approves Sage Therapeutics’ rapid-acting med...

The FDA on Friday approved Zurzuvae, a rapid-acting medicine from Sage Therapeut...

Organization behind ProMed defends move to subscription...

The organization that runs ProMed, an early warning system on disease outbreaks,...

Pandemic slowed cancer diagnoses, but late-stage cancer...

A new study emphasizes how, because of disruptions in care during the pandemic, ...

Pediatricians’ group reaffirms support for gender-affir...

Mark Del Monte, CEO of the American Academy of Pediatrics, called the restrictio...

STAT+: Pharmalittle: White House drug-shortage task for...

A new White House task force on drug shortages brainstormed policies for stemmin...

Opinion: The high out-of-pocket cost of donating a kidney

New York state recently passed a law reimbursing kidney donors. The federal gove...

STAT+: Medicare slashes safety net hospital payments on...

Safety net hospitals are getting almost $1 billion less next year to offset the ...

STAT+: For brain-computer interfaces, the commercial hu...

Brain-computer interfaces hold promise for paralysis, but the business challenge...

Mesoblast plans new GvHD trial after another FDA rejection

Mesoblast plans follows an FDA response to the BLA resubmission for remestemcel-...

Evox Therapeutics teams with New York medical school to...

Evox and the Icahn School of Medicine will develop gene delivery vectors for car...

Accord gears up to commercialise Hipra’s Covid-19 vacci...

Hipra’s Bimervax targets the alpha and beta viral variants, but the EMA recently...

Cellectis to focus on CAR-T cell therapies in 2023

Cellectis provided updates for the three CAR-T cell therapies trials, with the t...